Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Intellect Neurosciences and non-profit organization CHDI have entered an agreement under which CHDI will assess Intellect's Oxigon as a potential therapy for Huntington's disease. Intellect has completed Phase I clinical trials for Oxigon in elderly healthy volunteers.
Subscribe to our email newsletter
CHDI has access to a variety of relevant research tools, including in vitro and in vivo assays and animal models.
Intellect is the exclusive licensee of patents related to the use of Oxigon, which are owned jointly by New York University and the University of South Alabama Research Foundation. Patents have been granted in Europe, the US and several other countries.
Daniel Chain, CEO and chairman of intellect, said: “We are pleased that CHDI is evaluating whether Oxigon’s method of action might extend to Huntington’s disease. Oxigon is planned to enter Phase II clinical trials in Alzheimer’s patients in 2008. The data generated in the CHDI study could support proceeding with clinical trials in HD patients as well.”